UK Prime Minister Briefed on Israel-UK Collaborative Stem Cell Research
During a recent visit to Israel, British Prime Minister David Cameron, accompanied by Israel’s President, Shimon Peres, viewed an exhibition showcasing collaborative stem-cell research between the UK and the Hadassah Medical Organization.
Among the researchers who briefed the two leaders about her work was Dr. Sharona Even-Ramof Hadassah’s Goldyne Savad Institute of Gene Therapy, who discussed the use of regenerative cell therapy for Parkinson’s disease. In this particular joint project, embryonic stem cells are developed into nerve cells, which degenerate in Parkinson’s. Dr. Even-Ram is working on the project withProf. Kevin Shakesheffof the University of Nottingham.
Scientists from the two countries have been working together for the past two years on stem cell projects under a program directed by BIRAX, the British Israel Research and Academic Exchange Partnership Regenerative Medicine Initiative.BIRAX is a £10-million initiative of the British Embassy in Israel and the British Council, in collaboration with the Pears Foundation and the United Jewish Israel Appeal. It supports research that employs stem cell therapies to treat diseases such as Parkinson’s, Alzheimer’s, and diabetes. According to the British Council, over four million pounds has been committed to seven projects, “bringing together scientists in Britain and Israel to tackle some of the world’s most challenging health problems.”
The Institute of General Medicine comprises thirteen departments and nine Centers of Excellence. Each a leader in its field, the Centers include the Unit for the Early Detection of Colorectal Cancer, Center for Aging Research, National Center for Down Syndrome, and National SLE (LUPUS) Center. Its stellar Intensive Care Unit is world renowned.
Hadasit, Hadassah’s Technology Transfer Arm, Reviews
When the Hadassah University Medical Center’s physicians suggest a
solution to a medical problem which can lead to the development of a new
medicine or product, Hadasit, Hadassah’s technology transfer arm, explores its
feasibility and supports the promotion of those viable ideas with innovation
potential. Although 2012 has been “a year full of challenges for the life
science industry,” says Einat Zisman, Hadasit’s Chief Executive Officer,
Hadasit still signed 125 agreements for clinical trials, all to be done at
Hadassah. In addition, Hadasit signed 15 agreements for cooperation and
commercialization of technologies that were developed at Hadassah. Click here
to read the latest Newsletter from Hadasit >>